Wall Street Zen Downgrades Precipio (NASDAQ:PRPO) to Hold

Precipio (NASDAQ:PRPO) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Sunday.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Precipio in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

Precipio Price Performance

Shares of PRPO opened at $27.88 on Friday. Precipio has a one year low of $3.90 and a one year high of $29.53. The stock’s fifty day moving average is $24.65 and its 200-day moving average is $22.43. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.10 and a current ratio of 1.27. The firm has a market capitalization of $48.79 million, a price-to-earnings ratio of -34.00 and a beta of 1.22.

Institutional Trading of Precipio

A number of large investors have recently added to or reduced their stakes in PRPO. Susquehanna International Group LLP acquired a new position in Precipio in the third quarter worth approximately $194,000. Renaissance Technologies LLC lifted its position in shares of Precipio by 10.7% during the 4th quarter. Renaissance Technologies LLC now owns 14,500 shares of the biotechnology company’s stock valued at $333,000 after acquiring an additional 1,400 shares during the last quarter. Evernest Financial Advisors LLC acquired a new stake in shares of Precipio during the 3rd quarter valued at $374,000. Geode Capital Management LLC boosted its stake in shares of Precipio by 5.1% during the 4th quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock worth $377,000 after acquiring an additional 789 shares in the last quarter. Finally, Topline Capital Management LLC bought a new stake in shares of Precipio during the 3rd quarter worth $1,158,000. 10.45% of the stock is currently owned by institutional investors.

Precipio Company Profile

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.